Immunotherapy, which stimulates the body's immune system, has received a considerable
amount of press in recent years because of its powerful benefits. Cancer immunotherapy …

Immunotherapy is rapidly evolving secondary to the advent of newer immunotherapeutic
agents and increasing approval of the current agents by the United States Food and Drug …

Cancer immunotherapy has resulted in durable responses in patients with metastatic
disease, unseen with traditional chemotherapy. Several therapies have been approved by …

Immune checkpoint inhibitors (ICPIs) and chimeric antigen receptor (CAR) T-cell therapy are
two main promising methods of immunotherapy, which have become increasingly important …

With the advent of immunotherapeutic agents, durable and dramatic responses have been
observed in several hard-to-treat malignancies, outlining a roadmap to conquering cancer …

Immunotherapy through checkpoint inhibitors is now standard practice for a growing number
of cancer types, supported by overall improvement of clinical outcomes and better tolerance …

Over the last decade anticancer treatment has experienced encouraging changes. One of
the latest developments is immunotherapy, which is increasingly becoming a mainstay for …

Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several
cancers. While these immunotherapies have improved patient outcomes in many clinical …

Over the past two decades, immunotherapy has emerged as a promising treatment option
for patients with cancer. However, newer versions of immunotherapy, such as checkpoint …

Purpose: We aimed to elucidate predictive factors for the development of immune-related
adverse events (ir aes) in patients receiving immunotherapies for the management of …